Iodine-131 given for therapeutic purposes modulates differently interferon-γ-inducible α-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 4, 2007, Pages 1485-1490

  Antonelli, Alessandro ^a   Rotondi, Mario ^b   Fallahi, Poupak ^a   Grosso, Mariano ^a   Boni, Giuseppe ^a   Ferrari, Silvia Martina ^a   Romagnani, Paola ^b   Serio, Mario ^b   Mariani, Giuliano ^a   Ferrannini, Ele ^a,c  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IODINE 131;

ADULT; ARTICLE; AUTOIMMUNE THYROIDITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; GRAVES DISEASE; HUMAN; IMMUNE RESPONSE; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TH1 CELL; THYROID FUNCTION; TOXIC GOITER;

EID: 34147096595     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2006-1571     Document Type: Article

References (30)

1. Lazarus JH, Clarke S 1997 Use of radioiodine in the management of hyperthyroidism in the U.K.: development of guidelines. Thyroid 7:229-231
2. 131I treatment for nodular goitre. Int J Radiat Oncol Biol Phys 13:209-215
3. Teng WP, Stark R, Munro AJ, Young SM, Borysiewicz LK, Weetman AP 1990 Peripheral blood T cell activation after radioiodine treatment for Graves' disease. Acta Endocrinol (Copenh) 122:233-240
4. Zlotnik A, Yoshle O 2000 Chemokines: a new classification system and their role in immunity. Immunity 12:121-127
5. Arenberg DA, Polverini PJ, Kunkel SL, Shanafelt A, Hesselgesser J, Horuk R, Strieter RM 1997 The role of CXC chemokines in the regulation of angiogenesis in non-small cell lung cancer. J Leukoc Biol 62:554-562
6. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A 2001 Involvement of chemokine receptors in breast cancer metastasis. Nature 410:50-56
7. Rotondi M, Lazzeri E, Romagnani P, Serio M 2003 Role for interferon-γ inducile chemokines in endocrine autoimmunity: an expanding field. J Endocrinol Invest 26:177-180
8. Shimada A, Morimoto J, Kodama K, Suzuki R, Oikawa Y, Funae O, Kasuga A, Saruta T, Narumi S 2001 Elevated serum IP-10 levels observed in type 1 diabetes. Diabetes Care 24:510-515
9. Romagnani P, Rotondi M, Lazzeri E, Lasagni L, Francalanci M, Buonamano A, Milani S, Vitti P, Chiovato L, Tonacchera M, Bellastella A, Serio M 2002 Expression of IP-10/CXCL10 and Mig/CXCL9 in the thyroid and increased serum levels of IP-10/CXCL10 in the serum of subjects with recent onset Graves' disease. Am J Pathol 161:195-206
10. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Buonamano A, Ferrannini E, Serio M 2004 High levels of circulating CXCL10 are associated with chronic autoimmune thyroiditis and hypothyroidism. J Clin Endocrinol Metab 89:5496-5499
11. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Paolicchi A, Ferrannini E, Serio M 2005 Increase of interferon-γ inducible a chemokine CXCL10 but not β chemokine CCL2 serum levels in chronic autoimmune thyroiditis. Eur J Endocrinol 152:171-177
12. Rotondi M, Falorni A, De Bellis A, Laureti S, Ferruzzi P, Romagnani P, Buonamano A, Lazzeri E, Crescioli C, Mannelli M, Santeusanio F, Bellastella A, Serio M 2005 Elevated serum interferon-γ-inducible chemokine-10/CXC chemokine ligand-10 in autoimmune primary adrenal insufficiency and in vitro expression in human adrenal cells primary cultures after stimulation with proinflammatory cytokines. J Clin Endocrinol Metab 90:2357-2363
13. Garcia-Lopez MA, Sancho D, Sanchez-Madrid F, Marazuela M 2001 Thyrocytes from autoimmune thyroid disorders produce the chemokines IP-10 and Mig and attract CXCR3+ lymphocytes. J Clin Endocrinol Metab 86:5008-5016
14. Antonelli A, Rotondi M, Ferrari SM, Fallahi P, Romagnani P, Franceschini SS, Serio M, Ferrannini E 2006 Interferon-γ-inducible α-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-γ agonists. J Clin Endocrinol Metab 9:614-620
15. Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell'Unto E, Bruno-Bossio G, Nardi M, Bartolomei MP, Lepri A, Rossi G, Martino E, Pinchera A 1998 Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 338:73-78
16. Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren JG, Blomgren H, Taube A 1992 Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. N Engl J Med 326:1733-1738
17. Antonelli A, Fallahi P, Nesti C, Pupilli C, Marchetti P, Takasawa S, Okamoto H, Ferrannini E 2001 Anti-CD38 autoimmunity in patients with chronic autoimmune thyroiditis or Graves' disease. Clin Exp Immunol 126:426-431
18. Antonelli A, Ferri C, Fallahi P 1999 Thyroid cancer in patients with hepatitis C infection. JAMA 28:1588
19. Jones BM, Kwok CC, Kung AW 1999 Effect of radioactive iodine therapy on cytokine production in Graves' disease: transient increases in interleukin-4 (IL-4), IL-6, IL-10, and tumor necrosis factor-α, with longer term increases in interferon-γ production. J Clin Endocrinol Metab 84:4106-4110
20. Antonelli A, Miccoli P, Fallahi P, Grosso M, Nesti C, Spinelli C, Ferrannini E 2003 Role of neck ultrasonography in the follow-up of children operated on for thyroid papillary cancer. Thyroid 13:479-484
21. 131I therapy. Nucl Med Commun 19:341-346
22. Vitti P 2000 Grey scale thyroid ultrasonography in the evaluation of patients with Graves' disease. Eur J Endocrinol 142:22-24
23. Vitti P, Rago T, Mazzeo S, Brogioni S, Lampis M, De Liperi A, Bartolozzi C, Pinchera A, Martino E 1995 Thyroid blood flow evaluation by color-flow Doppler sonography distinguishes Graves' disease from Hashimoto's thyroiditis. J Endocrinol Invest 18:857-861
24. Stabin MG 1996 Internal radiation dosimetry. In: Henkin RE, Boles MA, Dillehay GL, Halama JR, Karesh SM, eds. Nuclear medicine. Vol I. St. Louis: Mosby; 316-333
25. Traino AC, Di Martino F, Grosso M, Monzani F, Dardano A, Caraccio N, Mariani G, Lazzeri M 2005 A predictive mathematical model for the calculation of the final mass of Graves' disease thyroids treated with 131I. Phys Med Biol 50:2181-2191
26. Grosso M, Traino A, Boni G, Banti E, Della Porta M, Manca G, Volterrani D, Chiacchio S, Al Sharif A, Borso E, Raschilla R, Di Martino F, Mariani G 2005 Comparison of different thyroid committed doses in radioiodine therapy for Graves' hyperthyroidism. Cancer Biother Radiopharm 20:218-223
27. Marinelli LD, Quinby EH, Hine GJ 1948 Dosage determination with radioactive isotopes. Practical considerations in therapy and protection. Am J Roentgenol 59:260-281
28. Siddiqi A, Monson JP, Wood DF, Besser GM, Burrin JM 1999 Serum cytokines in thyrotoxicosis. J Clin Endocrinol Metab 84:435-439
29. Nygaard B, Knudsen JH, Hegedus L, Scient AV, Hansen JE 1997 Thyrotropin receptor antibodies and Graves' disease, a side-effect of 131I treatment in patients with nontoxic goiter. J Clin Endocrinol Metab 82:2926-2930
30. Nygaard B, Jarlov AE, Kristensen LO, Faber J 2000 Serum levels of the cytokines IL-1β, IL-6 and ICAM-1 after 131I-treatment of Graves' disease and nodular goiter. Horm Metab Res 32:283-287